Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to veterans and first responders from New York state; establishes a psilocybin assisted therapy pilot program fund.
S01801 would amend New York’s Public Health Law to create a psilocybin assisted therapy pilot program administered by the Department of Health. The program would fund treatment for up to 10,000 participants and would end if psilocybin is approved for medical use by the federal Drug Enforcement Administration or a successor agency. Eligible participants would include veterans and their families, first responders, retired first responders, and people suffering from cluster headaches, but only if they reside in western New York.
The bill also defines key terms such as psilocybin, psilocin, medical psilocybin, certified medical use, and facilitator, and it directs the department to adopt regulations governing applications, funding, facilitator training, evaluation, and reporting. It authorizes the department to study the program’s implementation and effectiveness, conduct related research, and report to the governor and legislature every two years on outcomes and recommendations.
The bill would create a new state pilot program and a corresponding regulatory framework for psilocybin-assisted therapy, while also providing legal protections for patients, practitioners, and facilitators acting under the program. It would override conflicting provisions of the Public Health Law, exempt medical psilocybin from being treated as a “drug” for a specified Education Law article, and limit exposure to arrest, prosecution, civil penalties, licensing discipline, and certain collateral consequences when conduct is authorized by the section. It also includes confidentiality protections for patient records and public disclosure rules for facilitator information, while preserving employer impairment policies and avoiding conflicts with federal law or federal funding conditions.
The bill appears generally supportive of expanding access to psychedelic-assisted therapy, especially for veterans, first responders, and people with cluster headaches. Its structure as a pilot program, its reporting requirements, and its termination upon federal approval suggest a cautious, experimental approach rather than full statewide legalization. No committee transcript or vote data was provided, so there is no recorded legislative debate or voting sentiment in the supplied materials.
The main points of potential contention are the use of psilocybin, the scope of legal protections, and the bill’s interaction with federal law. The bill expressly avoids requiring any person or entity to violate federal law or risk federal contracts or funding, which indicates concern about federal preemption and institutional compliance. Another likely issue is the geographic limitation to western New York and the narrow eligibility categories, which may be viewed as either a targeted pilot design or an arbitrary restriction. Privacy and disclosure provisions for patient records and facilitator identities may also draw attention from supporters and opponents alike.